Treatment of systemic mastocytosis with interferon-γ: failure after appearance of anti-IFN-γ antibodies
Autor: | B. Heilig, Christoph Fiehn, O Prummer, Werner Hunstein, Harald Gallati |
---|---|
Rok vydání: | 1995 |
Předmět: |
medicine.medical_treatment
Clinical Biochemistry Biochemistry Antibodies Interferon-gamma medicine Humans Interferon gamma Treatment Failure Systemic mastocytosis Aged biology business.industry Granulocyte-Macrophage Colony-Stimulating Factor General Medicine Immunotherapy Eosinophil medicine.disease Mast cell Symptomatic relief Cytokine medicine.anatomical_structure Immunology biology.protein Female Interleukin-3 Interleukin-4 Antibody business Mastocytosis medicine.drug |
Zdroj: | European Journal of Clinical Investigation. 25:615-618 |
ISSN: | 1365-2362 0014-2972 |
Popis: | We report a case of a patient with systemic mastocytosis who was treated with interferon-gamma. Because of severe diarrhoea, nausea and weight loss due to mast cell infiltration of the gastric mucosa the patient received 150 micrograms d-1 interferon-gamma subcutaneously for 10 months. During therapy, the plasma concentrations of IL-3, IL-4 and GM-CSF, which seem to play a role in mast cell growth and differentiation were monitored. The patient had good symptomatic relief and the initially very high eosinophil counts in the peripheral blood showed a partial reduction. However, after 4 months of therapy the patient relapsed. In serum obtained after the relapse, but not in stored serum from the beginning of the therapy, neutralizing antibodies against interferon-gamma were found. Therefore an initial response to the therapy and a secondary failure mediated by treatment-induced antibodies against recombinant interferon-gamma might be suggested. Interferon-gamma may be a well tolerated therapeutic option in systemic mastocytosis. However, treatment-induced neutralizing antibodies against recombinant interferon-gamma should be considered if secondary treatment failure occurs. |
Databáze: | OpenAIRE |
Externí odkaz: |